Stanford researchers have developed a bispecific antibody treatment that targets multiple domains of the SARS-CoV-2 virus, specifically aimed at neutralizing various variants of concern. The treatment exhibits strong efficacy before infection but shows limited effectiveness post-infection, indicating it is not a direct therapeutic solution. The study was conducted in mice, highlighting that while promising, this method is in early stages and may indicate a future avenue for vaccine enhancement rather than an immediate treatment option.